Drug Approval | May 01, 2022
USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
Vacuum-Assisted Breast Biopsy (VABB) is an innovative and more effective alternative to the traditional method where benign lumps are removed surgically, leaving scars and causing distress
New kit enhances menu of FFPE solutions and allows oncology researchers to extract higher yields of concentrated DNA compared to traditional techniques
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Subscribe To Our Newsletter & Stay Updated
